Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing

Eli Lilly CEO Dave Ricks details the historical development and massive success of GLP-1 drugs, outlining the company's strategy for future innovation, supply chain expansion, and addressing pricing, access, and new therapeutic applications.

• Eli Lilly's GLP-1 drugs, like Mounjaro, are the result of nearly two decades of research and innovation, now leading the global pharmaceutical market.

• Lilly is actively working to reduce drug costs and improve insurance coverage for anti-obesity treatments while balancing the need for R&D investment in new therapies.

• The company is exploring GLP-1 applications beyond obesity, including mental health, addiction, and potentially general longevity, alongside significant investments in U.S. manufacturing.

Eli Lilly CEO Dave Ricks discusses the remarkable success of GLP-1 drugs like Mounjaro, which originated from an 18-year research journey. The company aims to make these treatments more accessible and affordable, pushing for insurance reimbursement for anti-obesity drugs, while also investing heavily in R&D to discover new therapeutic areas and develop an oral pill format. Lilly faces the challenge of balancing profitability with the social good of widely available, life-changing medicines.

The GLP-1 Journey

• 00:02:23 Eli Lilly's journey with GLP-1 drugs began in 2006 with the launch of the first GLP-1 drug for diabetes, which incidentally caused weight loss. Years of continuous innovation led to improved versions, culminating in Mounjaro (tirzepatide), which combines GLP-1 with another appetite-suppressing peptide. This breakthrough resulted from a 2014 scientific discovery and an early 2016 clinical trial in Singapore where healthy volunteers lost too much weight too quickly, signaling its immense potential.

Addressing Pricing and Access

• 00:07:54 Eli Lilly is committed to reducing GLP-1 drug pricing, having already lowered the out-of-pocket cost from $1,000 to $499. The company's primary goal is to secure insurance reimbursement for anti-obesity drugs, arguing that it is illogical for insurance to cover conditions like hypertension and ineffective surgeries but not preventive obesity treatments. Acknowledging a need to balance affordability with ongoing innovation, Lilly expects single-digit deflation in this category over time, emphasizing that drastically cutting prices would eliminate incentives for future R&D.

R&D, Supply Chain, and Biotech Market

• 00:09:07 Eli Lilly prioritizes allocating capital to organic R&D, currently employing 4,200 PhD scientists, a scale comparable to MIT and Harvard combined. The company is also heavily investing in supply chain buildout, constructing multiple capital-intensive, technically difficult injectable drug manufacturing plants in the U.S., creating thousands of jobs. Beyond internal innovation, Lilly actively acquires external innovation, especially given the current challenging biotech funding landscape, where venture funding has significantly decreased and many publicly traded biotechs trade at or below cash value.

Future Applications and Public Health

• 00:18:03 GLP-1 drugs are revealing unexpected 'pleotropic' benefits beyond weight loss, including reduced smoking, gambling, and online shopping behaviors. Eli Lilly is initiating clinical studies for tirzepatide in bipolar disorder and major depressive disorder, as well as addictive hedonic pathways, using a new GLP-1 variant with less weight loss but more brain activity. The company also supports broader public health reforms, advocating for changes to the food system to make quality food more accessible and expresses concern over misinformation regarding vaccines, while also acknowledging the positive role of AI in informing patients.